Download Breakout Session Overviews | Download Schedule of Breakout Sessions | View Conference Schedule
The close out stage is labor intensive and requires all functional areas to work collaboratively to ensure a timely and effective close out. Ms. Baker will describe the steps to close a study, what functional areas are involved and what actions are needed for the IRB as well as data review, regulatory review, safety review, and statistical review. 517
Presenter: Layla Baker, MBChB, MPH, CCRP, Senior Clinical Research Manager, Elevance Health/ Carelon Research
Ms. Rajakumaran will consider the process of how the Centre for Clinical Trial Support functions as a study coordinating centre in managing multi-centre Investigator Initiated trials. This includes, study intake, study start-up activities, getting sites activated, providing ongoing support to participating sites, data management, monitoring, regulatory submissions, and close-out. 519
Presenter: Subitha Rajakumaran, BSc, CCRP, Senior Project Manager, Trials Operations, Sunnybrook Research Institute
Ms. Reid will delve into the intricate journey of implementing a centralized monitoring approach at a large oncology academic medical center and explore the multifaceted challenges faced during the development phase. This session aims to provide an overview of the hurdles, focusing on data integrity, communication, standardization, regulatory compliance, site coordination, training, and technology integration. 521
Presenter: Rebecca Reid, BS, CCRA, Senior Clinical Research Monitor, University of Miami
What do we need to know about conducting Investigator Initiated Research with Supplements and Nutrients as pharmaceuticals? The prevalence and use of vitamins and supplements continues to rise. Ms. Wintering will discuss considerations when using supplements for self-care or as a test article in clinical research. Is Investigational New Drug application with FDA oversight required? Understanding the mechanism, clinical effect, optimal dosing, and side effects/drug interactions of all nutrients and supplements should be a primary goal of research. When participants use supplements regularly, what are the implications for safety in clinical research that uses other drugs? Ms. Wintering will discuss controversy and ethical considerations when using vitamins and supplements as pharmaceuticals. Case examples will be presented. 523
Presenter: Nancy Wintering, MSW, LCSW, CCRP, Assistant Director of Research, Thomas Jefferson University
Investigators with a novel study idea may require an Investigational New Drug Application or Investigational Device Exemption application. A sponsor’s responsibility is to assist investigators and study teams with every step of this process. 525
Presenter: Laura Adkins, MAP, BA, CCRP, CCRA, CRS, AdvCRS, Director, Office of Research Regulatory Affairs, University of Arkansas for Medical Sciences
Sponsor-Investigators are often unaware of the complete set of responsibilities they assume when taking on this dual role. Dr. Statler will provide training strategies and curriculum content intended to support the development of such education. 527
Presenter: Abby Statler, PhD, MPH, MA, CCRP, Director, Research Quality and Safety, Dartmouth-Hitchcock Medical Center
ADVANCING INNOVATION AND INTEGRITY:
A TIME FOR TRANSFORMATION IN CLINICAL RESEARCH
8 tracks I 20+ Topic Areas I 100+ Sessions I 70+CE